Royce & Associates LP Has $13.45 Million Stake in Organon & Co. (NYSE:OGN)

Royce & Associates LP increased its holdings in shares of Organon & Co. (NYSE:OGN) by 4.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 703,094 shares of the company’s stock after purchasing an additional 30,750 shares during the quarter. Royce & Associates LP’s holdings in Organon & Co. were worth $13,450,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. KBC Group NV raised its position in shares of Organon & Co. by 19.5% in the third quarter. KBC Group NV now owns 7,744 shares of the company’s stock valued at $148,000 after purchasing an additional 1,263 shares during the period. MQS Management LLC bought a new stake in Organon & Co. during the 3rd quarter worth approximately $202,000. Victory Capital Management Inc. boosted its stake in shares of Organon & Co. by 127.3% in the 3rd quarter. Victory Capital Management Inc. now owns 183,298 shares of the company’s stock valued at $3,506,000 after purchasing an additional 102,663 shares during the last quarter. Verus Capital Partners LLC boosted its stake in shares of Organon & Co. by 65.4% in the 3rd quarter. Verus Capital Partners LLC now owns 39,193 shares of the company’s stock valued at $750,000 after purchasing an additional 15,501 shares during the last quarter. Finally, Versor Investments LP boosted its stake in shares of Organon & Co. by 47.0% in the 3rd quarter. Versor Investments LP now owns 47,026 shares of the company’s stock valued at $900,000 after purchasing an additional 15,026 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Down 1.8 %

Organon & Co. stock opened at $15.03 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10. The firm’s fifty day moving average is $18.14 and its 200 day moving average is $19.94. The company has a market capitalization of $3.87 billion, a PE ratio of 2.98, a PEG ratio of 0.73 and a beta of 0.84.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the previous year, the firm earned $0.78 EPS. The firm’s revenue was up 4.1% on a year-over-year basis. As a group, sell-side analysts predict that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th will be issued a dividend of $0.28 per share. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 annualized dividend and a yield of 7.45%. Organon & Co.’s payout ratio is 22.22%.

Analyst Ratings Changes

OGN has been the topic of a number of analyst reports. JPMorgan Chase & Co. lowered shares of Organon & Co. from a “neutral” rating to an “underweight” rating and upped their price objective for the company from $18.00 to $20.00 in a research note on Friday, September 6th. Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.